◼ Archived
Business
Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Biotech
113 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
FDA offers new details on quicker approval pathway for personalized gene therapies
12 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Treasury's COINS rule draft would narrow the path for China biotech dealmaking, experts say
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Artiva to discontinue cell therapy after two patient deaths, cut workforce by 94%
Artiva Biotherapeutics is discontinuing its autoimmune cell therapy and cutting 94 percent of its staff following patient deaths.
◼ Archived
Business
Ferring Signs $1.4 Billion Deal to Buy Gameto Fertility Startup
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Why Anthropic's IPO contrasts the 'cult of Elon Musk' at SpaceX and Tesla
Anthropic's public offering filings spark intense financial competition, existential risk warnings, and sharp market scrutiny.
◼ Archived
Business
China urges US to halt proposed expansion of outbound investment curbs
China is calling for the United States to halt proposed expansions of outbound investment curbs targeting high-tech sectors and biotech deals.
◼ Archived
Business
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
The US Treasury is proposing the COINS Act to restrict high-tech investments in China, specifically targeting the biotech sector while exempting certain deals.
◼ Archived
World
Treasury expected to be harder on China biotech deals in new rules
The United States Treasury proposes new rules targeting high-tech and biotech investments in China.
◼ Archived
Business
Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
Gilead's oral drug succeeds in mid-stage ulcerative colitis trials, posting strong remission rates.
◼ Archived
Business
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
Merck KGaA acquires Silence Therapeutics for $1.3 billion following a phase 2 trial win for an siRNA drug.
◼ Archived
Business
Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Roche returns to China’s Hansoh for $15B biobucks ADC pact
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Beijing seeks tighter grip on AI exports amid US rivalry
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
◼ Archived
Business
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
Cancer vaccines emerge as a major focus for the N.I.H. through a newly announced public-private partnership.
◼ Archived
Business
Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
Caribou Biosciences, a biotech firm co-founded by Nobel laureate Jennifer Doudna, is halting its pipeline and reducing staff amid potential closure.
◼ Archived
Business
Why the FDA should not approve an ineffective multicancer screening test
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in mice
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Shionogi to Acquire IntraBio for $2 Billion
Japanese pharmaceutical company Shionogi has agreed to acquire Texas-based rare disease biotech IntraBio in a deal valued at $2 billion.
◼ Archived
Business
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
◼ Archived
Business
Introducing Fierce Biotech's 2026 Fierce 15
Fierce Biotech has unveiled its 2026 'Fierce 15' list, highlighting the most innovative and promising private biotechnology companies of the year.
◼ Archived
Business
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
◼ Archived
Business
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
◼ Archived
Business
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.
◼ Archived
Business
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
◼ Archived
Business
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
◼ Archived
Business
uniQure stock crashes as Huntington’s gene therapy data weaken
uniQure stock plummets alongside partner shares following disappointing clinical data from a Huntington's gene therapy trial.
◼ Archived
Business
UniQure’s gene therapy continues to slow Huntington’s progression after four years
UniQure shares tumble significantly as clinical trial data for its Huntington’s gene therapy draws conflicting reports.
◼ Archived
Business
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
◼ Archived
Business
Kodiak skyrockets on positive study data for 2 eye drugs
Kodiak stock surges after a Phase III clinical victory for its Eylea rival targeting wet AMD.
◼ Archived
Business
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
◼ Archived
Business
Kodiak Sciences stock soars on positive AMD trial data
Kodiak Sciences shares surged over 90% following positive Phase 3 trial results for an eye disease drug targeting AMD.
◼ Archived
Technology
AI co-scientists are revolutionizing how research is done
A biotech startup run by thousands of AI agents discovers a promising lung-cancer drug, sparking global attention.
◼ Archived
Business
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
Endpoints News has revealed the 2026 Endpoints 11, spotlighting the most exciting startups currently shaping the biotechnology landscape.
◼ Archived
Business
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
◼ Archived
Business
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna advances its cell therapy toward an FDA submission as new one-year durability data emerges.
◼ Archived
Business
Anthropic CEO says AI could cure most major diseases within next decade
Anthropic reports its AI model Claude discovered a novel CRISPR-like enzyme system.
◼ Archived
Business
Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
Enveda secures $311 million in venture funding to advance nature-derived AI drugs into clinical trials.
◼ Archived
Business
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
◼ Archived
Business
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
◼ Archived
Business
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
Grail stock surges over 30 percent as the FDA reviews its multi-cancer early detection blood test.
◼ Archived
Business
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
Moderna shares surge toward a 52-week high as upcoming melanoma vaccine data commands attention at the ESMO Congress.
◼ Archived
Business
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
Alkermes reports positive Phase Ib trial data for ALKS 7290, sparking significant market and medical interest.
◼ Archived
Business
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
Telix's $2.35 billion merger with ITM signals a bold move into radiopharmaceuticals, drawing analyst optimism.
◼ Archived
Business
Updated: Electra says $350M IPO will help it become a commercial biotech
Immunology drugmaker Electra Therapeutics pursues an upsized $350 million initial public offering on Nasdaq under the ticker ETRA.
◼ Archived
Science
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development
2 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
Novo Nordisk signs a licensing agreement worth up to $1.4 billion with Orbis Medicines to develop oral therapeutics.
◼ Archived
Business
Definium's LSD-based anxiety, depression drug scores another trial win
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
◼ Archived
Business
🔮 fades ✓
How Novartis' Double-Stacked Failures Shook Biotech
Novartis is facing significant scrutiny within the biotech sector following a series of dual failures that have impacted investor confidence.
◼ Archived
Business
🔮 fades ✗
Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
◼ Archived
Business
🔮 holds ✗
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
Roivant Sciences stock surges as its experimental inhaled lung disease drug hits mid-stage study goals.
◼ Archived
Business
🔮 fades ✗
Inhibrx claims first win for long-sought immunotherapy target
Inhibrx claims a first-of-its-kind win for a long-sought immunotherapy target with new clinical data.
◼ Archived
Business
🔮 fades ✓
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.
◼ Archived
Business
🔮 holds ✗
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.